Immunotherapy plus oral chemotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older and your breast cancer has spread to other parts of the body.
- You have not received more than one line of chemotherapy for your metastatic breast cancer.
- You have been treated with anthracyclines (like doxorubicin) or taxanes (like paclitaxel) in the past.
- You must have at least one tumor that can be measured on a scan.
- You are medically fit enough to receive this treatment, with normal organ function (like kidneys, liver, and bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.